Peer-influenced content. Sources you trust. No registration required. This is HCN.

British Medical Journal (The BMJ)Nirmatrelvir and Risk of Hospital Admission or Death in Adults with COVID-19: Emulation of a Randomized Target Trial Using Electronic Health Records

In a study of 256,288 individuals who tested positive for COVID-19 and had at least one risk factor for developing severe COVID, regardless of immunization, booster, or prior infection history, treatment with nirmatrelvir reduced rates of hospital admission or death at 30 days.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form